Fundraising FoxCumulus Oncology
5 known investors
Find your way into Cumulus Oncology
Sign up to see every warm intro you have to Cumulus Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cumulus Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cumulus Oncology is a drug development company specializing in oncology therapeutics, leveraging experienced leadership with track records in new drug applications and successful M&A transactions. The company builds a risk-adjusted portfolio in the life sciences and pharmaceutical sector.
Founders & leadership
Investors · 5
How we know: funding news · businesswire.com · the VCSheet dataset · Not right? Tell us
How we know: Scottish National Investment Bank's portfolio page · the Companies House PSC register · funding news · globenewswire.com · Not right? Tell us
Funding
SEC filings, press & company announcements$5.6M disclosed across 1 of 3 rounds · 2022–2024
- Undisclosed amountseed financingJan 2024
Eos Advisory (lead), Scottish National Investment Bank
Source ↗ - $5.6MraisedFeb 2022 · 2 sources
Eos Advisory (lead), Scottish Enterprise
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Companies House · registry record
View on Companies House ↗- Registered name
- CUMULUS ONCOLOGY LIMITED
- Company number
- SC581311
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 13 Nov 2017
- Registered office
- 61 Dublin Street, Edinburgh, Midlothian, EH3 6NL
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology72190 — Other research and experimental development on natural sciences and engineering
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 12 Nov 2025 · next due 26 Nov 2026
Current officers · 7
- James Alexander Fair — secretary, appointed 8 Sept 2023
- Manuel Alves Aivado — director, appointed 7 Jul 2025
- Brian Michael Gallagher Jr — director, appointed 9 Dec 2024
- Catherine Elizabeth Lewis La Torre — director, appointed 1 Jun 2024
- Andrew Paul Mcneill — director, appointed 9 Jun 2020
- Keith Murdoch — director, appointed 9 Jun 2020
- Clare Jane Wareing — director, appointed 13 Nov 2017
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Cumulus Oncology do?
- Cumulus Oncology is a drug development company specializing in oncology therapeutics, leveraging experienced leadership with track records in new drug applications and successful M&A transactions. The company builds a risk-adjusted portfolio in the life sciences and pharmaceutical sector.
- Who founded Cumulus Oncology?
- Cumulus Oncology was founded by Catherine.
- Who are Cumulus Oncology's investors?
- Cumulus Oncology's investors include Alba Equity, Apollo Informal Investment, Eos Advisory, Scottish National Investment Bank, Scottish Enterprise.
- How much funding has Cumulus Oncology raised?
- Cumulus Oncology has disclosed $5.6M raised across 1 of its 3 known rounds.